SUSTAINABILITY OF RARE DISEASE FUND AND AVAILABILITY OF DONOR-AUTHORISED PRINCIPAL FOR CELL, TISSUE AND GENE THERAPY PRODUCTS
Imported from official source
This version
- Version
- 1 of 1
- Recorded
- October 07, 2026 04:33
- Change
- Initial
- Content hash
3e516358de0fa0490467b789c1250ce6- All versions
- Revision history